CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
Company to open new headquarters in 2024
Anandiben Patel, Governor, Uttar Pradesh will inaugurate the two-day celebrations
The 9th World Ayurveda Congress and Arogya Expo 2022 aims to showcase the efficacy and strength of the AYUSH systems of medicine at the global level
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Subscribe To Our Newsletter & Stay Updated
